Reviewing the use of corticosteroids in bronchopulmonary dysplasia

Objective: Review the risks and benefits of postnatal corticosteroid use for the treatment of bronchopulmonary dysplasia, considering that there is not a more effective therapy. Data sources: The literature review was carried out in the Bireme database, using the terms “bronchopulmonary dysplasia an...

Full description

Bibliographic Details
Main Authors: Fernanda Aparecida de Oliveira Peixoto, Paulo Sérgio Sucasas Costa
Format: Article
Language:Portuguese
Published: Brazilian Society of Pediatrics 2016-03-01
Series:Jornal de Pediatria (Versão em Português)
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2255553615001834
_version_ 1811192959271436288
author Fernanda Aparecida de Oliveira Peixoto
Paulo Sérgio Sucasas Costa
author_facet Fernanda Aparecida de Oliveira Peixoto
Paulo Sérgio Sucasas Costa
author_sort Fernanda Aparecida de Oliveira Peixoto
collection DOAJ
description Objective: Review the risks and benefits of postnatal corticosteroid use for the treatment of bronchopulmonary dysplasia, considering that there is not a more effective therapy. Data sources: The literature review was carried out in the Bireme database, using the terms “bronchopulmonary dysplasia and corticosteroid” in the Lilacs, Ibecs, Medline, Cochrane Library, and SciELO databases, selecting the most relevant articles on the subject, with emphasis on recent literature published in the last five years. Summary of the data: In preterm infants, bronchopulmonary dysplasia is still a common problem and remains without a specific therapy, despite knowledge of the several risk factors. The treatment essentially consists of supportive measures, but in the past, corticosteroids were widely used, as they are the only medications that have an impact on disease progression. However, the emergence of cerebral palsy associated with the indiscriminate use of corticosteroids has prevented the prescription of this drug in the last 15 years. Since then, no new measures have been taken, and the incidence of the disease tended to increase during this period, creating the need for a review of corticosteroid use and, possibly, more restricted indications. Conclusions: The association between risks and benefits of corticosteroid use in preterm infants needs to be considered due to the fact that some infant subpopulations may show more benefits than risks, such as those using mechanical ventilation with difficult weaning.
first_indexed 2024-04-12T00:00:35Z
format Article
id doaj.art-5bfe860a00de4ce59764d260f7eebbfb
institution Directory Open Access Journal
issn 2255-5536
language Portuguese
last_indexed 2024-04-12T00:00:35Z
publishDate 2016-03-01
publisher Brazilian Society of Pediatrics
record_format Article
series Jornal de Pediatria (Versão em Português)
spelling doaj.art-5bfe860a00de4ce59764d260f7eebbfb2022-12-22T03:56:14ZporBrazilian Society of PediatricsJornal de Pediatria (Versão em Português)2255-55362016-03-0192212212810.1016/j.jpedp.2015.12.009Reviewing the use of corticosteroids in bronchopulmonary dysplasiaFernanda Aparecida de Oliveira Peixoto0Paulo Sérgio Sucasas Costa1Departamento de Pediatria, Faculdade de Medicina, Universidade Federal de Goiás (UFG), Goiânia, GO, BrasilDepartamento de Pediatria, Faculdade de Medicina, Universidade Federal de Goiás (UFG), Goiânia, GO, BrasilObjective: Review the risks and benefits of postnatal corticosteroid use for the treatment of bronchopulmonary dysplasia, considering that there is not a more effective therapy. Data sources: The literature review was carried out in the Bireme database, using the terms “bronchopulmonary dysplasia and corticosteroid” in the Lilacs, Ibecs, Medline, Cochrane Library, and SciELO databases, selecting the most relevant articles on the subject, with emphasis on recent literature published in the last five years. Summary of the data: In preterm infants, bronchopulmonary dysplasia is still a common problem and remains without a specific therapy, despite knowledge of the several risk factors. The treatment essentially consists of supportive measures, but in the past, corticosteroids were widely used, as they are the only medications that have an impact on disease progression. However, the emergence of cerebral palsy associated with the indiscriminate use of corticosteroids has prevented the prescription of this drug in the last 15 years. Since then, no new measures have been taken, and the incidence of the disease tended to increase during this period, creating the need for a review of corticosteroid use and, possibly, more restricted indications. Conclusions: The association between risks and benefits of corticosteroid use in preterm infants needs to be considered due to the fact that some infant subpopulations may show more benefits than risks, such as those using mechanical ventilation with difficult weaning.http://www.sciencedirect.com/science/article/pii/S2255553615001834Bronchopulmonary dysplasiaCorticosteroidsTreatment
spellingShingle Fernanda Aparecida de Oliveira Peixoto
Paulo Sérgio Sucasas Costa
Reviewing the use of corticosteroids in bronchopulmonary dysplasia
Jornal de Pediatria (Versão em Português)
Bronchopulmonary dysplasia
Corticosteroids
Treatment
title Reviewing the use of corticosteroids in bronchopulmonary dysplasia
title_full Reviewing the use of corticosteroids in bronchopulmonary dysplasia
title_fullStr Reviewing the use of corticosteroids in bronchopulmonary dysplasia
title_full_unstemmed Reviewing the use of corticosteroids in bronchopulmonary dysplasia
title_short Reviewing the use of corticosteroids in bronchopulmonary dysplasia
title_sort reviewing the use of corticosteroids in bronchopulmonary dysplasia
topic Bronchopulmonary dysplasia
Corticosteroids
Treatment
url http://www.sciencedirect.com/science/article/pii/S2255553615001834
work_keys_str_mv AT fernandaaparecidadeoliveirapeixoto reviewingtheuseofcorticosteroidsinbronchopulmonarydysplasia
AT paulosergiosucasascosta reviewingtheuseofcorticosteroidsinbronchopulmonarydysplasia